At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
In Brief
A Phase 3 clinical trial evaluating Salsalate and Placebo for Type 2 Diabetes. Completed, enrolled 277 participants across 16 sites.
Detailed Summary
Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study will determine whether salicylates represent a new pharmacological option for diabetes management. The study is conducted in two stages. The first stage is a dose ranging study, administering salsalate compared to placebo over three months. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk. The second stage is a second trial and posted under alternate registration.
Study Details
Timeline
Interventions
Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
Placebo to Salsalate